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ABSTRACT

Xiang Xiao, M.S. Department of Pharmacology and Toxicology, Wright State
University, 2013. Effects of Ang 1-7 and Cellular Vesicles on Ang II-Induced
Dysfunction and Apoptosis in Cerebral Endothelial Cells.

Angiotensin II (Ang II) induces endothelial dysfunction and is implicated in the
pathogenesis of vascular diseases. Angiotensin 1-7 (Ang 1-7) has been
reported to counteract many deleterious effects of Ang II. Endothelial
microvesicles (EMVs) are small membrane vesicles released from endothelial
cells (ECs) undergoing stress and apoptosis. But their functions are largely
unknown. In this study, we investigated the effects of Ang 1-7 and EMVs on
apoptosis and dysfunction of human brain microvascular endothelial cells
(HbmECs). Reactive oxygen species (ROS) and nitric oxide (NO) production,
and Nox2, p-Akt/Akt, p-eNOS/eNOS expression were analyzed. We found that
Ang II dose-dependently induced HbmEC apoptosis and that both Ang 1-7 and
EMVs can counteract the effects of Ang II. Their protective effects were
associated with ROS/NO production which were linked to Nox2, and Akt
/eNOS pathways. Our data suggests that both Ang 1-7 and EMVs protect
endothelial dysfunction and apoptosis induced by Ang II in HbmECs.
iii
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I.

INTRODUCTION

Part 1: Angiotensin Axis and Endothelial Dysfunction
Renin angiotensin system (RAS)
The renin angiotensin system (RAS) is a hormonal cascade in regulation of
cardiovascular, renal, and adrenal function that governs body fluid and
electrolyte homeostasis, as well as arterial pressure. It has been extensively
studied since the first description of renin by Tigerstedt and Bergmann in 1898.
The classical RAS consists of a circulating endocrine system in which the
principal effector hormone is Angiotensin (Ang) II. Ang II is a biologically active
octapeptide that is produced by the action of renin on angiotensinogen to form
Ang I and then subsequently convert to Ang II by Ang-converting enzyme
(ACE). The actions of Ang II are mediated via the Ang type 1 receptor (AT1
receptor). However, the current view of RAS system is characterized by an
increased complexity, as evidenced by the discoveries of new functional
components and actions of the RAS, including local tissue RAS, a (pro)renin
receptor, ACE2, Ang 1-7, Mas receptor, the function of the Ang type 2 receptor
(AT2 receptor). Studies have demonstrated the importance of a tissue RAS in
the brain, heart, blood vessels, adrenal glands, kidney and etc [1-5].
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Although some of the components that necessary for the biosynthesis of the
active peptide product (Ang II) may be taken up from the circulation into the
tissue, the local tissue RAS defines the de novo tissue generation of Ang II and
its interaction with Ang II receptor on the same (autocrine) or adjacent
(paracrine) cells [6].

The RAS cascade (Fig 1) is activated in response to reduced perfusion which
result in renin secretion and release into circulation [6]. Renin cleaves the
angiotensinogen to form the inactive decapeptide Ang I. The catabolism of Ang
I serves as a point of divergence in the system, leading not only to the
production of the bioactive octapeptide Ang II by ACE [7], but also to the
formation of the active peptide Ang 1-7 by prolylendopeptidase and neprilysin
[8]. ACE2 is a recently identified homologue of ACE, which can catalyze Ang I
to Ang 1-9 [9], with subsequent conversion to Ang 1-7 by ACE or
neutral-endopeptidase [10]. ACE2 is also highly effective in the conversion of
Ang II to Ang 1–7, which has approximately 400-fold more affinity to Ang II
than to Ang I [11]. Ang II can further be degraded by aminopeptidase (AMP)
and dipeptidyl-aminopeptidase to produce Ang III and Ang IV, respectively [12].
Of note, Ang IV can be produced from Ang III by the activity of AMP. Ang 1-7
can be metabolized by ACE to form the inactive degradation products Ang 1-5
[13].
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Figure 1. RAS cascade. AGT: angiotensinogen; Ang: angiotensin; ACE:
angiotensin-converting enzyme; AT1 R: Ang II type 1 receptor; AT2 R: Ang II
type 2 receptor; Mas R: Ang 1-7 receptor; AMP: aminopeptidase; D-Amp:
dipeptidyl-aminopeptidase; PCP: prolyl-carboxypeptidase; PEP:
prolylendopeptidase; NEP: neutral-endopeptidase; (P)RR: (pro)renin receptor.

The physiological and pathological roles of RAS
The RAS is a complex regulatory system which plays an important role in
mediating both physiological and pathological functions. The main
physiological stimuli for RAS activation are low salt intake, blood volume and
BP. In turn, Ang II acts to help raise blood volume and BP, thereby prevent
hypovolemia and hypotension.
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The main physiological roles of RAS are: 1) to prevent life-threatening
shrinkage of intravascular volume (rapid actions of Ang II). 2) to help achieve
sodium balance without large alterations in BP (slower actions of Ang II). 3) to
increase the efficiency of cardiovascular dynamics by promoting the growth of
the heart and vessels, and sensitizing blood vessels to vasoconstrictor agents
(slowest actions of Ang II). The functions of the RAS from the general point of
view is being homeostatic. However it will be harmful if carried to excess.
Indeed, increased activity of the RAS, especially in combination with other
cardiovascular risks factors, may lead to a cascade of deleterious effects such
as hypertension, cardiovascular hypertrophy, oxidative stress with endothelial
dysfunction, atherosclerosis and tissue inflammation [14]. In recent years, the
pathophysiological implications of the system have been the main focus of
attention, inhibitors of the RAS such as ACE inhibitors and Ang II receptor
blockers have become important clinical tools in the treatment of
cardiovascular and renal diseases such as hypertension, heart failure, and
diabetic nephropathy [15].

Two counteracting axes in RAS
There are two counteracting axes that exist in RAS: ACE/Ang II/AT1 receptor
axis and ACE2/Ang 1-7/Mas receptor axis. The ACE/Ang II/AT1 receptor is a
classical RAS axis. Ang II produced from Ang I by ACE is a well-known
bioactive substance in the regulation of blood pressure and is involved in the
exaggeration of vascular disease [16]. The major receptor subtypes for Ang II
are the AT1 and AT2 receptors. Both the AT1 and the AT2 receptors belong to
4

the superfamily of G protein-coupled receptors that contains seven
transmembrane regions. They share about 34% homology and have distinct
signal transduction pathways. The distribution of AT1 receptor covers most
organs [17], whereas AT2 receptor expression is observed in only a few
organs after birth and is up-regulated in pathological states [18;19]. AT1
receptor stimulation mediates the classical major actions of Ang II and is
known to cause vasoconstriction, inﬂammation, ﬁbrosis, cellular
growth/migration and ﬂuid retention (Table 1) [20]. These findings are also
closely related to the development of RAS inhibitors, such as ACE inhibitors
(ACEi) and AT1 receptor blockers (ARBs), promoting the basic and clinical
research in the RAS. Accordingly, They are widely used as antihypertensive,
cardiovascular and renoprotective drugs with well-documented effectiveness.
Nevertheless, important limitations have been reported related to the use of
these drugs. For instance, besides their potential side effects, the responses to
ACEi treatment are inﬂuenced by gender and ethnic diversity and ARBs have
limited efficacy in treatment of end-organ damage [21]. AT2 receptor
stimulation appears to antagonize the effects mediated by AT1 receptor
stimulation. Therefore, AT2 receptor stimulation could contribute to the effects
of ARBs [18;19;22].

The ACE2/Ang 1–7/Mas axis has been highlighted as the counteracting
partner of the ACE/Ang II/AT1 receptor axis. Ang 1-7 is now recognized as a
biologically active component of RAS since it exerts a vast array of actions,
many of them opposite to those attributed to Ang II. It was initially regarded as
5

an inactive component of the RAS for many years. However, in recent years,
two pivotal discoveries clearly established Ang 1-7 as an active RAS mediator.
First, the existence and characterization of ACE2, which was established later
as the main Ang 1-7 forming enzyme [23;24]. Second, the G-protein coupled
Mas receptor was discovered as a functional receptor for its endogenous
ligand Ang 1-7 [25]. In mammals, Mas receptor is expressed predominantly in
brain and testis with moderate levels of expression in heart and kidney [26;27].
Thus, Ang 1-7 is now considered a biologically active member of the RAS,
which binds to Mas receptor to induce many beneﬁcial actions, such as
vasodilation, inhibition of cell growth, anti-inflammation, anti-thrombosis and
anti-fibrosis [28;29].

RAS Axis

ACE/Ang II/AT1 R

ACE2/Ang 1-7/Mas R

Substrate

Ang I

Ang II

Enzyme

ACE

ACE2

Receptor

AT1

Mas

Effects

Vasoconstriction;
inflammation;
thrombosis; fibrosis;
sodium reabsorption
cellular migration

Vasodilatation;
anti-inflammation;
anti-thrombosis; anti-fibrosis;
anti-hypertrophy;
antiproliferation

Metabolites

Ang 1-7 (by ACE2)
Ang III (by AMP)
Ang IV (by D-AMP)

Ang 1-5 (by ACE)

Table 1. Two counteracting axes in RAS. Ang I: angiotensin I; Ang II:
angiotensin II; Ang 1-7: angiotensin 1-7; ACE: angiotensin converting enzyme;
ACE2: angiotensin converting enzyme 2; AT1: angiotensin II type 1 receptor;
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Mas: angiotensin 1-7 receptor; AMP: aminopeptidase; D-Amp:
dipeptidyl-aminopeptidase; Ang1-5: angiotensin 1-5; Ang III: angiotensin III
(2-8).

Ang II/Ang 1-7 balance regulates endothelial function
Endothelium is the active inner monolayer of the blood vessels, forming an
interface between circulating blood and the vessel wall. It represents the
largest organ in the body and plays a critical role in vascular homeostasis.
Endothelial cells regulate vascular tone by releasing various contracting and
relaxing factors including nitric oxide (NO), arachnoid acid metabolites,
reactive oxygen species (ROS), and vasoactive peptides. In addition, the
endothelium actively regulates vascular permeability, inflammatory activity, cell
proliferation, as well as the balance between coagulation and fibrinolysis.
Endothelial dysfunction is referred as impaired endothelium-dependent
vasodilation (reduction of the bioavailability of vasodilators and increase of
endothelium-derived contracting factors). In addition to that, endothelial
dysfunction also comprises a specific state, which is characterized by
increased vascular permeability, cell proliferation, and a proinflammatory and
prothrombotic phenotype (including leucocyte-endothelial interactions and
increased adhesion and aggregation of platelets) [30;31].

Oxidative stress

can induce vascular endothelial dysfunction. ROS are generated at sites of
inflammation and injury. It can function as signaling molecules that participate
in the regulation of fundamental cell activities such as cell growth and cell
adaptation responses at low concentrations; whereas, ROS can cause cellular
7

injury and death at higher concentrations [32]. Exogenous ROS can be
produced from pollutants, tobacco, smoke, drugs, xenobiotics, or radiation.
What's more, ROS can be produced intracellularly through multiple
mechanisms, the major sources being mitochondria, peroxisomes,
endoplasmic reticulum, and the nicotinamide adenine dinucleotide phosphate
(NADPH) oxidase complex in the cell membranes.
Ang II has significant pro-inflammatory actions in the vascular wall, inducing
the production of ROS, cytokines, adhesion molecules and chemokines [33].
The endothelial dysfunction caused by Ang II is mainly through the reduction of
NO bioavailability and imbalance between the ROS and antioxidant capacity.
In endothelial cells (Figure 2), NADPH oxidase catalytic subunit gp91phox
(Nox2) is activated by Ang II when it binds to the AT1 receptor [34]; The
NADPH oxidase (Nox) regulatory subunit p47phox is phosphorylated and
translocated to p22phox. Increased p47phox-p22phox complex formation
initiated Nox activation and subsequently ROS over-production [35]. Enhanced
production of ROS (mainly O2-) are known to induce programmed cell death in
the vascular ECs [36]. The pro-apoptotic effect of endogenous ROS induced
by Ang II in ECs seems to involve the disturbance of mitochondrial membrane
permeability, which is a prerequisite for cytochrome c release. The cytochrome
c is regulated by the Bcl-2 protein family [37]. The Bcl-2 protein family can
either promote (e.g., Bax) or inhibit apoptosis (e.g., Bcl-2, Bcl-XL). An
imbalance between anti-apoptotic and pro-apoptotic members of Bcl-2 protein
family will increase the mitochondrial membrane permeability, and then trigger
the release of cytochrome c from the space between the inner and outer
8

mitochondrial membrane into the cytoplasm [36]. In the cytoplasm, the
complex formation of cytochrome c and apoptotic peptidase activating factor 1
(Apaf1) stimulates caspase-9 release, which results in the activation of
caspase-3, which eventually leads to EC apoptosis.
Through the detailed mechanism of Ang 1-7 counteracts the actions of Ang II
remains unclear, accumulating evidences suggest that Ang 1-7 may oppose
the endothelial dysfunction and apoptosis induced by Ang II either through
directly inhibiting the activity of Nox or through stimulating NO production and
subsequently inhibition of apoptosis executioner proteases (caspases) (Figure
2) [38;39].

Ang II

Ang 1-7
AT1 R

NAD(P)H
Oxidase
P22 P47

Mas R

?
?

p-Akt
ROS

p-eNOS

PI3K

NO
Mitochondria
Caspase-3
Apoptosis

Cytoplasm
Dysfunction

Endothelial cells

Figure 2. Ang II/Ang 1-7 balance in regulating endothelial cell function: Nox
and Akt/eNOS signaling pathways. Ang II: angiotensin II; Ang 1-7: angiotensin
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1-7; AT1 R: angiotensin II type 1 receptor; Mas R: Mas receptor; Nox:
NAD(P)H oxidase; PI3K: phosphoinositide 3-kinases; p-Akt: protein Kinase B
phosphorylation; eNOS: endothelial nitric oxide synthase. ROS: reactive
oxygen species; NO: nitric oxide.

PI3K/Akt/eNOS signaling pathways in endothelial cells
NO plays a critical role in endothelial function by maintaining vasodilator tone,
inhibiting platelet aggregation and adhesion [40]. Many risk factors implicated
in cardiovascular diseases seem to be associated with impairment in the NO
system [40;41]. Phosphoinositide 3-kinases (PI3K) and its downstream
serine/threonine kinase Akt (also known as Protein Kinase B) play a central
role in promoting the survival of a wide range of cell types, including ECs [42].
PI3K constitutes a multifunctional family of enzymes activated by receptor
tyrosine kinases, G protein coupled receptor and other stimuli. Upon receptor
activation, PI3K subunit is recruited to the plasma membrane and binds to
inositol lipids. These lipids serve as docking sites for proteins that harbor
pleckstrin-homology domains, including Akt and its upstream activator
phosphoinositide-dependent kinases 1 (PDK1). Once in the membrane, Akt is
phosphorylated by PDK1, leading to the activation of Akt. Akt activation
mediates the phosphorylation of endothelial NO synthase (eNOS), and thereby
stimulates eNOS activity and increases NO release. Previous studies have
found that Ang II had a biphasic effect on Akt phosphorylation [43;44]. It is
suggested that low concentration Ang II causes a dose-dependent increase in
Akt phosphorylation, while high concentration of Ang II lead to a decrease of
10

Akt phosphorylation in ECs [43;44]. Recent studies have suggested that Ang
1-7 regulates EC function through functionally active Mas receptor, which
stimulates eNOS activity and NO production through Akt-dependent pathways
[45;46].

Part 2: Extracellular Vesicles and Endothelial Dysfunction
Extracellular vesicles
The extracellular space of multicellular organisms contains solutions of
metabolites, ions, proteins and polysaccharides. However, it is clear that this
extracellular environment also contains a large number of mobile
membrane-limited vesicles for which the term of extracellular vesicles is
suggested [47]. Extracellular vesicles are shed in response to cell activation,
dysfunction, injury, or apoptosis. Major types of extracellular vesicles are
exosomes, microvesicles (MVs) and apoptotic bodies (Figure 3). There is an
increasing interest in the field on MVs and exosomes, whose release may
represent a universal and evolutionarily conserved process.

Key features of MVs and exosomes
The key features (table 2) of exosomes include: 1) Exosomes are vesicles
surrounded by a phospholipid bilayer (approximately 50–100 nm in diameter),
their size range roughly overlaps that of the viruses [47]. 2) Exosomes are an
end-product of the endocytic recycling pathway. First, endocytic vesicles form
at the plasma membrane and fuse to form early endosomes. They become
late endosomes where intraluminal vesicles (ILVs) bud off into the lumen.
11

These multivesicular bodies (MVBs) then directly fuse with the plasma
membrane and release exosomes into the extracellular space. 3) Exosomes
have been predominantly characterized in the case of immune cells (dendritic
cells, T cell, B cells, macrophages) and tumors. 4) They feature
phosphatidylserine (PS) on the outer membrane leaflet and exosomal markers
such as CD63, CD81 and CD9 [48;49]. 5) Isolation methods include a slow
centrifuge at 1500g for 15 minutes followed by 100 nm gravity-driven filtration.
Exosomes are final pellet at 120,000 x g for 70 minutes [47]. For purer
preparations, some researchers use sucrose gradient ultracentrifugation. 6)
Transmission electron microscopy has been typically used to characterize
exosomes due to their small size. Western blot and mass spectroscopy have
been used to identify the proteomic profiles of exosomes. Bead-coupled flow
cytometry can also be used to detect exosomes [47;50].

The key features (table 2) of MVs include: 1) MVs are structures surrounded
by a phospholipid bilayer (approximately 100–1000 nm in diameter). Their size
range overlaps that of bacteria and insoluble immune complexes [51]. 2) They
are formed by regulated release by budding/blebbing of the plasma membrane.
3) They have been predominantly characterized as products of platelets, red
blood cells and ECs. 4) They feature PS on the outer membrane leaflet [52],
tissue factor (TF) and cell specific markers. however, some observations also
suggest the existence of MVs without PS externalization [52]. 5) Routine
isolation methods include a slow centrifuge at 1500g for 15 minutes and
followed by centrifuge at 18,000g for 30 min or 100,000g for 60 min [53].
12

6) Flow cytometry is the commonest method for detecting MVs, transmission
electron microscopy (TEM) and nanoparticle tracking analysis (NTA) were also
used to detecting MVs [54;55].

Exosomes

MVs

Size Range

30–100 nm in diameter

0.1 -1 µm in diameter

Biogenesis

Exocytosis of MVBs

Budding from plasma
membrane

Markers

CD63, CD81, CD9, and
Tsg101

Annexin V binding, TF
and cell-specific markers

Table 2. Key features of exosomes and MVs. MVBs: multivesicular bodies; TF:
tissue factor.

Potential use of endothelial-derived MVs and exosomes as biomarkers
and their functional significance
Both MVs and exosomes are released when cells undergo stress, activation or
apoptosis. They can carry the characteristics of their parent cells, which enable
them to serve as potential biomarkers for various diseases [47;56;57]. Of note,
they also have been shown to mediate cell communications through the ability
of transferring membrane proteins, phospholipids and RNAs from their parent
cells to distant cells [58]. Recent novel pharmacological approaches have
started to reveal the functions of MVs and exosomes.

13

Endothelial MVs (EMVs) result from endothelial plasma membrane blebbing
and carry endothelial proteins such as vascular endothelial cadherin
(VE-cadherin or CD144), E-selectin (CD62E), platelet endothelial cell
adhesion molecule-1 (CD31) [59], intercellular cell adhesion molecule
(ICAM)-1 (CD54), endoglin (CD105) , S-endo (CD146) or αv integrin (CD51)
[60]. Among these, only CD62E and CD144 are the exclusive markers for
EMVs. Like other MVs, EMVs also can transfer functional proteins and nuclear
materials such as DNA, mRNA, and miRNA to target cells [58]. Although EMVs
represent a sparse population of circulating MVs, their changes in plasma level
might predict important clinical information [49]. The level of circulating EMVs
are inversely correlated with the amplitude of flow-mediated dilatation in
patients presenting endothelial dysfunction, independently of age and
pressure [61].

The functional significance of EMVs has been proposed in recent years. Abid
Hussein et al. first documented that EMV release could protect EC from
apoptosis by diminishing caspase-3 level in cultured ECs [62]. EMVs
contribute to the sorting of pro-apoptotic factors and the prevention of cell
detachment and apoptosis. Moreover, EMVs carrying endothelial protein C
receptor and activated protein C could also promote cell survival by inducting
cytoprotective and anti-inflammatory effects [63]. One recent publication has
described that the EMVs could protect ECs against apoptosis induced by
camptothecin and that inhibition of p38MAPK activity is involved in
EMV-mediated anti-apoptotic effect [64]. In most cases, the role of EMV
14

carried nuclear materials remains to be determined. A pioneering study by
Deregibus et al. showed that endothelial progenitor cell derived MVs
(EPC-MVs) were able to trigger an angiogenic program to ECs through
shuttling mRNAs associated with the PI3K/AKT/eNOS signaling pathway [65].
Recently, Cantaluppi et al. suggested that EPC-MVs carrying miR-126 and
miR-296 for inducing the activation of PI3K/Akt/eNOS signaling pathway in
islet endothelium that may sustain revascularization and β-cell function [66].
Endothelial exosomes are produced in MVBs during endocytosis and are
well-known for antigen presentation [47]. Unlike MVs, they express specific
exosomal markers such as CD63, Alix, tetraspanins and tumor susceptibility
gene 101 (TSG101) [67]. Endothelial exosomes can serve as biomarkers
since they contain functional proteins, mRNAs and miRNAs [68]. A recent
study suggests that endothelial miR-214 containing exosomes repress the
expression of ataxia telangiectasia in recipient ECs, thereby prevent
senescence [59]. This emerging field is still relatively young considering the
vast wealth of information,

15

II.

HYPOTHESISES AND AIMS

Part 1
Hypothesis:
It is hypothesized that Ang 1-7 protects hbmECs from Ang II-induced HbmEC
dysfunction and apoptosis through down-regulation of Nox2 and activation of
PI3K/Akt/eNOS signaling pathway.
Specific Aims:
Aim 1: To develop optimal concentration of Ang II for inducing HbmEC
apoptosis.
Aim 2: To evaluate the effects of Ang II/Ang 1-7 on HbmEC apoptosis, tube
formation ability, ROS and NO production.
Aim 3: To analyze the expression of Nox2, p-Akt/Akt and p-eNOS/eNOS.
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Part 2
Hypothesis:
It is hypothesized that EMVs could serve as novel therapeutic resource for
protecting HbmEC from dysfunction induced by Ang II.
Specific Aims:
Aim 1: To develop optimal procedures for EMV isolation and characterization.
Aim 2: To analyze the effects of EMVs on HbmEC tube formation ability, ROS
and NO production.
Aim 3: To analyze the effects of EMVs on HbmEC expression of p-Akt/Akt and
p-eNOS/eNOS.
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III.

EXPERIMENTAL DESIGNS

Part 1
Aim 1:
HbmECs were cultured with Ang II treatment at different concentration (0, 10-9,
10-8, 10-7, 10-6 M) for 24 hours. Then, the cells were collected and labeled with
Annexin V/PI for apoptosis assay using flow cytometry. Passages 4-13th of
HbmECs were used for the study.
Aim 2:
HbmECs were pre-treated with different concentrations of Ang 1-7 (0, 10-9, 10-8,
10-7, 10-6 M) for 1 hour and followed by Ang II (10-7 M) treatment for 24 hours.
Then, the cells were collected and labeled with Annexin V/PI for apoptosis
assay using flow cytometry.
After the Ang 1-7 effective concentration (10-7 M) was identified, HbmECs were
divided into seven treatment groups: vehicle; Ang II (10-7 M); Ang 1-7 (10-7 M);
Ang II + Ang 1-7, Ang II + losartan (10-6 M); Ang II + Ang 1-7 + A779 (10-7 M) or
+LY294002 (20 µM). Cells were collected for various assays: tube formation,
cell apoptosis, ROS and NO production. Passages 4-13th of HbmECs were
used for the study.
Aim 3:
HbmECs were treated in the same conditions as Aim 2. Then, the proteins
were extracted from treated cells and used for analyzing Nox2, p-Akt/Akt and
18

e-NOS/eNOS expression by western blot. Passages 4-13th of HbmECs were
used for the study.

HbmEC Treatment Groups

Control Ang II Ang 1-7

Apoptosis Tube formation
(FC)
(Cell culture)

Ang II
+
Ang 1-7

Ang II
+
Losartan

ROS production
(DHE staining & FC)

Ang II/Ang 1-7
+
A779

Ang II/Ang 1-7
+
LY294002

NO production Nox2, p-Akt/Akt
(DAF-FM staining) & p-eNOS/eNOS
(WB)

Figure 3: Experiment design for part 1. HbmECs: human brain microvascular
endothelial cells; Ang II: angiotensin II; Ang 1-7: Angiotensin 1-7; FC: flow
cytometry; ROS: reactive oxygen species; NO: nitric oxide; DHE:
dihydroethidium; DAM-FM: 4-amino-5-methylamino- 2’,7’-difluorofluorescein;
WB: western blot.
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Tube formation Assay Demonstration
Incubate plate for 1 hour at
37°C allowing Matrigel
matrix to solidify

Add 250 μl Matrigel
matrix per well of
24-well plate

Trypsinize, harvest
and count HbmECs

Add HbmECs (2 x 104 cells/ well)
on the top of solidified matrix
solution

Label tubes with 8 μg/ml
BD calcein AM in HBSS
and incubate for 30
minutes at 37°C

Incubate plate for 16
– 24 hours at 37°C
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Note: Tubes were
quantified by counting
sprouting capillary-like
structures exhibiting
lengths four times their
width.

Figure 4: Detailed HbmEC tube formation assay demonstration.
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Part 2
Aim 1:
HbmECs were staved under no-serum medium for 24 hours. HbmEC culture
medium was collected and centrifuged at 1500g for 15 min. Supernatant was
collected and subjected to 100 nm filter under gravity-driven force. EMVs were
retrieved from the up-membrane of that filter using sterile PBS and followed by
ultracentrifuged at 100,000g for 1 hour. EMV surface markers (Annexin V and
CD144) were determined by flow cytometry. The morphology was examined by
TEM. The size distribution and concentration were determined by NTA.
Aim 2:
HbmECs were divided into three treatment groups: Vehicle, Ang II (10-7 M),
Ang II + EMVs (10 µg/ml). Cells were collected for various assays: tube
formation, cell apoptosis, ROS and NO production. Passages 4-13th of
HbmECs were used for the study.
Aim 3:
HbmECs (passages 4-13th) were treated in the same conditions as Aim 2.
Then, the proteins were extracted from treated cells and used for analyzing
p-Akt/Akt and e-NOS/eNOS expression by western blot.
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HbmECs
Culture media centrifugation (1500g, 15min)
Filtration (100 nm pore)
Ultracentrifugation (10,000g, 60 min)

Surface marker CD144
(FC)

Morphology
(TEM)

Size & level
(NTA)

Figure 5: Experiment design for part 2 (EMV isolation & characterization).
HbmECs: human brain microvascular endothelial cells; EMVs: endothelial cell
microvesicles; FC: flow cytometry; TEM: transmission electron microscopy;
NTA: Nanosight tracking analysis.
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EMV Function Assay
HbmEC treatment groups

Vehicle

Ang II
+
EMVs (10 μg/ml)

Ang II
(10-7M)

(24hrs)

Tube formation
(cell culture)

ROS production
(DHE staining & FC)

NO production
(DAM-FM staining)

p-Akt/Akt &
p-eNOS/eNOS
(WB)

Figure 6: Experiment design for part 2 (EMV function assay). HbmECs: human
brain microvascular endothelial cells; Ang II: angiotensin II; EMVs: endothelial
cell microvesicles; FC: flow cytometry; ROS: reactive oxygen species; NO:
nitric oxide; DHE:

dihydroethidium; DAM-FM: 4-amino-5-methylamino-

2’,7’-difluorofluorescein; WB: western blot.
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IV.

MATERIALS AND METHODS

HbmEC Culture
Human brain microvascular endothelial cells (HbmECs) were purchased from
Cell Systems Corp. (Kirkland, WA, USA). HbmECs were cultured in CSC
complete medium (Cell Systems) containing 10% serum, supplemented with 2%
human recombinant growth factors (CSC CultureBoost-R, Cell Systems) and
0.2% Bac-OffR antibiotic solution (Cell Systems) under standard cell culture
conditions (37°C, 5% CO2). Cells of 4 to 13 passage were used in this study.
During cell growth, medium was changed every 2 or 3 days after washed 1
time with phosphate buffer saline (PBS) and replaced with fresh CSC complete
medium. Upon confluence, cells were detached using a passage reagent
group (Cell Systems) following manufacturer’s protocol, resuspended in CSC
complete medium and replated in tissue culture well. Precoated with
attachment factor (Cell Systems) is a necessary step before seeding cells.
Subsequently, cells were maintained in CSC complete medium prior to the
assays.

HbmEC characterization was performed by double staining of cultured cells
with 1,1’-dioctadecy1-3,3,3’,3’-tetramethylindocarbocyanine-labeled
acetylated low-density lipoprotein (DiI-acLDL) and Lectin from Bandeiraea
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simplicifolia (BS-lectin). Briefly, cells were incubated with DiI-acLDL (10µg/ml;
Biomedical Technologies, Stoughton, USA) at 37°C for 1 hour. Cells were then
fixed with 0.5% paraformaldehyde (PFA) for 10 minutes, and incubated with
FITC-conjugated Bs-lectin (20µg/ml; Sigma-Aldrich, St. Louis, USA) at 4°C for
4 hours. The cells were also stained with nuclear staining dye
4',6-diamidino-2-phenylindole (DAPI; 1 μg/ml; Wako Pure Chemical Industries
Ltd, Osaka, Japan) for 20 min at room temperature (RT). After the staining,
cells were examined with an inverted fluorescent microscope (EVOS,
Washington, USA). Double-stained cells for both Bs-lectin and DiI-acLDL were
considered as HbmECs.

Isolation of EMVs
Confluent cells were starved by subjecting to CSC serum free medium for 24
hours. After starvation, the supernatant of HbmEC culture was collected and
centrifuged at 1500g for 15 minutes to remove cell and cell debris. The
supernatant was then subjected to 100 nm syringe filter (CellTreat,
Gaithersburg, MD, USA) under gravity-driven force. EMVs (particle size
around 100 nm to 1um) on the upper membrane of filter were retrieved by
using syringe pump containing PBS and centrifuged at 100,000g for 60
minutes at 4 °C.

Characterization of EMVs
Isolated EMVs were characterized by flow cytometry based on the surface
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markers of EMVs. CD144 was used to identify events as EMVs. For analysis of
EMVs, freshly isolated MVs were resuspended in PBS and incubated for 30
min at RT in the dark with 5 μl of PE-conjugated anti-mouse CD144 (1:25,
eBioscience). Isotype matched PE-labeled nonspecific antibody
(Sigma-Aldrich) was served as negative control. After incubation, size
calibration of EMVs was performed using 1 and 2 µm flow cytometry beads
(Molecular Probes, Invitrogen, Eugene, OR). Labeled EMVs were subjected to
flow cytometric analysis. The flow cytometer (BD Accuri C6, San Jose, USA)
was set to acquire 100,000 events/sample. The EMVs were defined as
particles with size smaller than 1 µm, and CD144+ events, in the gate of MVs.
Transmission electron microscopy (TEM) was used to determine the size and
morphology of EMVs. The EMVs pellets were fixed with 500 µl 2%
glutaraldehyde in 1x PBS for 1 hour at 4°C and centrifuged again at 30,000 × g
for 30 min. The samples were washed with 1x PBS for 3 times (1 minute each),
fixed with 1% osmium tetroxide (OsO4) in 1x PBS for 2 hours at 4°C and
washed another 3 times (1 minute each), then dehydrated with a graded
ethanol series (50%, 75%, 95%, 100%) for 5 minutes each. Subsequently, the
samples were treated with 100% propylene oxide 2 times (5 minute each), and
then treated with 1:2 ratio of spurrs resin and propylene oxide, followed by a
2:1 ratio of spurrs resin and propylene oxide for 2 hours. Finally, the samples
were embedded in beam capsules with spurrs resin according to the
manufacture’s instruction, baked at 60°C in a hot air oven overnight. Ultrathin
sections (60 nm) were prepared with MT7000 and mounted on 300-mesh
copper grids, stained with 2% uranyl acetate for 5 minutes, rinsed with double
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distilled water for 5 times, and allowed to dry. The specimens were then
stained with lead citrate for 10 min (REYNOLDS, 1963), rinsed with double
distilled water another 5 times and allowed to air dry. Finally, all specimens
were examined with an EM 208 (Philips) transmission electron microscope at
an accelerating voltage of 70 KV. EMVs were visible as small (100 - 1000 nm),
rounded objects with clear, intact membranes.
NanoSight LM10 instrument (NanoSight, Amesbury, UK) was used to measure
the size and concentration of EMVs. When samples contained higher numbers
of particles (over 2 × 108/ml), they were diluted using PBS before analysis, and
the relative concentration was then calculated according to the dilution factor.
A video of 30 to 60s duration was taken with a frame rate of 30 frames/s, and
particle movement was analyzed by NTA software (version 2.2, NanoSight).
The NTA software is optimized to first identify and then track each particle on a
frame-by-frame basis, and its Brownian movement is tracked and measured
from frame to frame. In NTA, the paths of MVs acting as point scatters,
undergoing Brownian motion. The velocity of particle movement is used to
calculate particle size distribution by applying the two-dimensional
Stokes–Einstein equation. Since MVs have a low refractive index, their range
of sizes that can be analyzed by NTA using low refractive index, and the
smallest detectable size using the NTA system is approximately 50 nm. NTA
postacquisition settings were optimized and kept constant between samples,
and each video was then analyzed to give the mean, mode, and median
vesicle size together with an estimate of the concentration.
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Incorporation of EMVs In Target Cells
To study the capacity of EMVs to incorporate into HbmECs, EMVs were
labeled with PKH-26 dye (1 x 10-6 M, Sigma-Aldrich) for 30 min at 37 °C. After
that, EMVs were washed twice with sterile PBS and centrifuged at 100,000g
for 60 minutes. After that, EMVs were resuspended and washed in sterile PBS.
HbmEC were incubated with PKH26-labeled EMVs for different time frames
(0.5, 3, 6, 12, 24 hours). After 3 washing steps with PBS, HbmECs were fixed
in 2% paraformaldehyde (PFA) for 20 minutes. Nuclei were stained with DAPI
(1 μg/ml, Wako Pure Chemical Industries Ltd) for 10 minutes. Incorporation of
EMVs into HbmEC was observed by fluorescence light microscopy.

Apoptosis Assay
For cell apoptosis assay, we used the FITC Annexin V Apoptosis Detection Kit
(BD Biosciences, CA, USA). Briefly, the cells after different treatments were
collected and washed twice with cold PBS, and then resuspended in 100 µl 1X
Annexin-binding buffer. After that, 5 µl FITC-conjugated Annexin V and 5 µl
propidium iodide (PI) were added into cell suspension. The samples were then
gently vortexed and incubated at RT ( ~25°C) for 15 min in the dark. The
apoptotic cells were recognized as Annexin V+ / PI- cells. The percentage of
apoptotic cells was analyzed by flow cytometer (BD Accuri C6, San Jose,
USA).

Tube Formation Assay
HbmEC tube formation assay was performed by using a tube formation assay
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kit (BD Biosciences). Briefly, BD Matrigel matrix solution was thawed on ice
overnight, and 250μl of chilled BD Matrigel matrix (10 mg/ml) was place in
each well of a 24-well culture plate at 37°C for 1 hour to allow the matrix
solution to solidify. HbmECs were replated (2 X 104 cells/well) on top of the
solidified matrix solution and incubated at 37°C for 24 hours. After that, tubes
were labeled by adding 300 μl/well of 8 μg/ml BD calcein AM in Hanks
Balanced Salt Solution (HBSS) and incubated for 30 minutes at 37°C. After
that, labeling solution was removed and plate was washed twice with HBSS.
HbmEC tube formation was evaluated with an inverted fluorescence
microscope (EVOS, Washington, USA). Tubes were quantified by counting
sprouting capillary-like structures exhibiting lengths four times their width. Five
independent fields were assessed for each well, and the average number of
tubes per field was determined.

Measurement of ROS Generation
Intracellular ROS production in HbmECs was determined by dihydroethidium
(DHE) (Invitrogen Molecular Probes, Eugene, OR, USA) staining and followed
by flow cytometric analysis. DHE is a cell-permeable compound that upon
entering the cells, it interacts with O2- to form oxyethidium, which in turn
interacts with nucleic acids to emit a bright red color detectable qualitatively by
fluorescent microscope. Briefly, HbmECs were incubated with DHE (2 μmol/L)
in dark for 30 min and rinse off excess DHE with PBS twice. Red fluorescence
was visualized by an fluorescence microscopy. After that, HbmECs were
trypsinized and collected by centrifuge at 300g, 8 minutes, 4°C. Fluorescence
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intensity was analyzed by a flow cytometer (BD Accuri C6, San Jose, USA).
For each sample, 10,000 events were collected.

Determination of Nitric Oxide Production
The membrane-permeable indicator diaminofluorescein diacetate (DAF-FM
DA)

(Life technology, Grand Island, NY, USA) was used to assess NO

production released by HbmECs. This FAF-FM DA is converted by intracellular
esterases to form the DAF-FM, which reacts with NO to form green fluorescent
product. Briefly, cells were loaded with 10 μM DAF-FM DA in CSC serum free
medium (37°C for 60 minutes, in dark), washed twice with PBS and incubated
with CSC serum free medium (37°C for 30min, in dark) for de-esterification of
the intracellular diacetates. DAF-FM DA fluorescence was visualized by
inverted fluorescence microscopy and measured using a spectrofluorometer.

Western Blot Analysis
The levels of Nox2, Akt/p-Akt and eNOS/p-eNOS in HbmECs were determined
by western blot analysis. Cells were harvested after different treatments and
resuspended in Lysis-M reagent containing complete protease inhibitor tablets
(1 tablet/10 ml lysis reagent, Roche Diagnostics, Germany). Pipette thoroughly,
followed by vortex-mixing. keep it on ice and sonicated for 3 times. Centrifuge
the sample at 13,000g for 5 minutes at RT, transfer the supernatant (protein) to
a new tube. Proteins were subjected to sodium dodecyl sulfate polyacrylamide
gel electrophoresis (SDS-PAGE, 12% Bis-Tris Novex mini-gel, Invitrogen) and
transferred onto polyvinylidene difluoride (PVDF) membrane (Invitrogen). The
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PVDF membrane was blocked by incubating with 5% non-fat dry milk and
Tris-buffered saline with Tween 20 (TBS-T; 1X TBS with 0.1% Tween-20) for 1
hour and then incubated with antibodies against Nox2 (1:1000; Abcam), p-Akt
(1:1000; Cell Signaling Technology), p-eNOS (1:1000; Cell Signaling
Technology), Akt (1:1000; Cell Signaling Technology), eNOS (1:1000; Cell
Signaling Technology) at 4°C overnight. β-actin (1:4000, Sigma, MO) was used
to normalize protein loading. After being washed with TBS-T for 3 times (5
minutes each), membranes were incubated with horseradish peroxidase (HRP)
conjugated IgG (1:40000, Jackson Lab) for 1 hour at RT. Blots were then
developed with enhanced chemiluminescence developing solutions and
quantified.

Statistical Analysis
Results are expressed as means ± SEM of at least four experiments.
Differences between 2 groups were performed by the Student t-test. Multiple
comparisons were analyzed by 1- or 2-way ANOVA. For all tests, a P<0.05
was considered significant. All comparisons were performed using the
statistical package SPSS 16.0 for Window.
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V.

RESULTS

1. Characterization of HbmECs
The cultured HbmECs showed a typical, cobblestone morphology of ECs
(Figure 7A). When cultured under standard conditions (37°C, 5% CO2).
HbmECs were defined as cells binding with Bs-Lectin (Figure 7B) and
up-taking Di-acLDL (Figure 6C).

Blank
A

Bs-Lectin

Dil-acLDL

B

C

DAPI

Merge

D

E

Figure 7. Characterization of HbmECs by Dil-acLDL and Bs-lectin double
staining. A: HbmECs without staining, cells showed a typical, cobblestone
morphology of ECs; B: Bs-Lectin staining
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(Green); C: Di-acLDL up-taking

(Red); D: DAPI nuclear staining (Blue); E: Di-acLDL and Bs-Lectin positive
cells (Yellow); scale bar: 200 µm.

2. The dose-response effect of Ang II on HbmEC apoptosis
To determine whether Ang II is involved in programmed cell death, HbmECs
were treated with various concentrations (0, 10-9, 10-8, 10-7, 10-6 M) of Ang II
for 24 hours. Flow cytometric assay of Annexin V/PI staining showed that Ang
II dose-dependently induced apoptosis in HbmECs (Figure 8). HbmECs
treatment with 10-8 M, 10-7 M and 10-6 M of Ang II increased the apoptotic
rate by about 2.2-, 2.6- and 2.5-fold when compared to control (basal medium)
(P<0.01; n=4). There was no signiﬁcant difference between the apoptotic rate
in cells cultured with 10-9 M Ang II and control, whereas the apoptotic rate is
significant higher in cells treated with Ang II at the concentration of 10-7 M than
10-9 M (P<0.05, n=4). Thus, the concentration of Ang II was established by
using 10-7 M for further experiments.
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Figure 8. The dose-dependent effect of Ang II on HbmEC apoptosis. HbmECs
were treated with Ang II at different concentration (0, 10-9, 10-8, 10-7, 10-6 M) for
24 hours, and then cells were collected and subjected to cell apoptosis
analysis. n = 4. #P<0.05 vs vehicle; * P<0.05 vs 10-9 M Ang II.
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3. Ang 1-7 improves the tube formation ability compromised by Ang II in
HbmECs
As shown in Figure 8, the ability of HbmEC tube formation was attenuated in
Ang II-treated group by about 36% when compared with control (P<0.01).
Pretreatment with Ang 1-7 enhanced tube formation ability of HbmECs by 42%
(P<0.05) when compared with Ang II alone. Moreover, losartan and A779
blocked Ang II-induced impairment and Ang 1-7-induced enhancement of tube
formation in HbmECs, respectively (P<0.01).

A: HbmEC tube formation
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Figure 9. Ang 1-7 improves the tube formation ability of HbmECs compromised
by Ang II. A: Representative tube formation figures. A1: vehicle; A2: Ang II;
A3:Ang 1-7; A4: Ang II + Ang 1-7; A5: Ang II + losartan;

A6: Ang II + Ang 1-7

+ A779; scale bar: 200 µm. B: Summarized data. Data are the mean ± SEM, n
= 4. ## P<0.01 vs Control, ++P<0.01 vs Ang II, &&P<0.01 vs Ang II + Ang 1-7.

4. The dose-response effect of Ang 1-7 on cell apoptosis induced by Ang
II in HbmECs
To quantify the anti-apoptotic effects of Ang 1–7 on Ang II-induced apoptosis
on

bmECs, ﬂow cytometry analysis after Annexin V/PI staining was

conducted (Figure 10A). The percentage of Annexin V-positive stained cells
was enhanced by exposure to Ang II (10-7 M) alone compared to control cells
(P<0.01). Pretreatment with Ang 1-7 markedly reduced the apoptotic rate
caused by Ang II, and the degree of suppression was significantly increased at
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higher concentrations (10-7 and 10-6 M) of Ang 1-7. Thus, the concentration of
Ang 1-7 was established by using 10-7 M for further experiments.
We used receptor/pathway blockers to further determine the mechanism in
apoptotic effect of Ang II and anti-apoptotic effect of Ang 1-7, respectively
(Figure 10B). Measurement of annexin V/PI staining by flow cytometry also
showed that Ang II mainly induced early apoptosis (Annexin V+/PI- events).
10-7 M Ang II signiﬁcantly increased the rate of apoptosis to 23.8 ± 7%
(P<0.01), 10-7 M Ang 1–7 alone had no effect on the rate of apoptosis of
HbmECs compared with the control group (P>0.05). Pre-incubation with Ang
1-7 attenuated Ang II-induced apoptosis (P<0.01). Ang II-induced apoptosis
was inhibited by AT1 receptor antagonist losartan (10-7 M) (P<0.01). The Mas
receptor antagonist A-779 (10-6 M) almost completely abolished the protective
effects of Ang 1–7 on HbmEC apoptosis (P< 0.01). The PI3K inhibitor
LY294002 (20 μM) partially abolished the protective effects of Ang1–7 on
HbmEC apoptosis (P<0.01).
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Figure 10. Ang 1-7 decreases apoptosis induced by Ang II in HbmECs. A:
HbmECs were pre-treated with different concentrations of Ang 1-7 (0, 10-9,
10-8, 10-7, 10-6 M) for 1 hour and followed by Ang II (10-7 M) treatment for 24
hours. B: Data summary for HbmEC apoptosis under different treatment
groups. Data are the mean ± SEM, n = 4. ##P<0.01 vs Control, ++P<0.01 vs
Ang II, &P<0.05, &&P<0.01 vs Ang II + Ang 1-7.

5. Ang 1-7 decreases the production of ROS induced by Ang II in
HbmECs
DHE fluorescent dye and flow cytometric analysis were used to investigate the
effect of Ang 1-7 on Ang II-induced ROS production. Results showed that DHE
fluorescence (red) was increased by about 2.7-fold after 24 hours stimulation
of Ang II (Figure 11A). Pretreatment with Ang 1-7 reduced the intensity of DHE
fluorescence by about 37% when compared with Ang II, reflecting a reduction
in ROS generation. Flow cytometric analysis (Figure 11B) showed that the
peak of the signal moved to the right, corresponding to increased DHE
fluorescence after incubation with Ang II. This increase in fluorescence
intensity was markedly reduced, as evidenced by a leftward shift after
treatment with Ang 1-7 in addition to Ang II, which reflected a reduction in ROS
generation. The effects that induced by Ang II and Ang 1-7 were neutralized by
their receptor antagonist losartan and A779, respectively. The protective effect
of Ang 1-7 is partially blocked by the PI3K inhibitor (LY294002).
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Figure 11. Ang 1-7 decreases Ang II-induced ROS production. A:
Representative DHE staining images observed under microscope. A1: vehicle;
A2: Ang II; A3: Ang 1-7; A4: Ang II + Ang 1-7; A5: Ang II + losartan; A6: Ang II
+ Ang 1-7 + A779; A7: Ang II + Ang 1-7 + LY294002; scale bar: 400 µm. B:
Representative flow cytometric figures. B1: analysis control; B2: vehicle; B3:
Ang II; B4: Ang 1-7; B5: Ang II + Ang 1-7; B6: Ang II + losartan; B7: Ang II +
Ang 1-7 + A779; B8: Ang II + Ang 1-7 + LY294002. C: Summarized data. Data
are the mean ± SEM, n = 4. ## P<0.01 vs Control, ++P<0.01 vs Ang II,
&P<0.05, && P<0.01 vs Ang II + Ang 1-7.
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6. Ang 1-7 increases the production of NO compromised by Ang II in
HbmECs
The NO production was lower (vs control; P<0.01; Figure 12) in the Ang
II-treated HbmECs. Ang 1-7 treatment increased the NO production in
HbmECs by about 1.8-fold when compared to control. Pre-treatment of Ang
1-7 and losartan induced 1.72- and 1.62-fold of NO production in Ang II-treated
group (P<0.01). In addition, A779 blocked those effects induced by Ang 1-7
(P<0.01), and LY294002 partially blocked the NO production induced by Ang
1-7 treatment (P<0.01).
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Figure 12. Ang 1-7 increases NO production of HbmECs compromised by Ang
II . A: Representative DAM-FM staining figures. A1: vehicle; A2: Ang II; A3:Ang
1-7; A4: Ang II + Ang 1-7; A5: Ang II + losartan;

A6: Ang II+ Ang 1-7 + A779;

A7: Ang II + Ang 1-7+ LY294002; scale bar: 200 µm. B: Summarized data.
Data are the mean ± SEM, n = 4. # P<0.05, ## P<0.01 vs Control, ++P<0.01
vs Ang II, &&P<0.01 vs Ang II + Ang 1-7.

7. Ang 1-7 counteracts Ang II on Nox2, p-Akt/Akt and p-eNOS/eNOS
expression in HbmECs
Ang II has been shown to increase Nox2 expression (P<0.01; Figure 13B),
treatment with Ang 1-7 decreased Nox2 expression when compared with Ang
II treatment (P<0.01; Figure 13B). Ang 1-7 has been shown to increase eNOS
activity in an EC culture model, and to also induce NO production in human
studies. However, the mechanism through which Ang 1-7 improves NO
production in ECs has not been well defined. We hypothesized that Ang 1-7
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could active the phosphorylation of Akt (p-Akt) and eNOS (p-eNOS), and
ultimately increase NO production. Treatment with Ang II decreased the
expression of p-Akt and p-eNOS (P<0.05 or 0.01; Figure 13C and D). Whereas,
treatment with Ang 1-7 increased the expression of p-Akt and p-eNOS (P<0.05
or 0.01; Figure 13C and D), Co-treatment of Ang 1-7 with Ang II increased
p-Akt and p-eNOS expression in HbmEC. In addition, losartan (AT1 receptor
antagonist) was able to block those effects of Ang II-induced on HbmECs，
A779 (Mas receptor antagonist) and LY294002 (PI3K inhibitor) were able to
block those effects of Ang 1-7-induced on HbmECs. Our results also showed
that addition of Ang II, Ang 1-7 or both have no changes in Akt or eNOS protein
levels. The Ang II impairment of p-Akt and p-eNOS are not equivalent, with the
reduction of p-Akt being greater. This suggests that another serine kinase may
also be important in the phosphorylation of eNOS.
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Figure 13: Ang 1-7 counteracting the effects of Ang II on Nox2, p-Akt/Akt and
p-eNOS/eNOS expression in HbmECs. A: Representative western blot bands
for Nox2, p-Akt/Akt and p-eNOS/eNOS. B: Summarized data for Nox2. C:
Summarized data for p-Akt/Akt. D: Summarized data for p-eNOS/eNOS. Data
are the mean ± SEM, n = 4. #P<0.05 vs control; +P<0.05, ++P<0.05 vs Ang II;
&&P<0.01 vs Ang II + Ang 1-7.

8. EMV characterization
Flow cytometric analysis of EMVs was performed to determine the size and
phenotype of EMV. Isolated EMVs were analyzed by using anti-CD144. The
EMVs were defined as CD144 + (Figure 14 A3) MVs, at gate R1 with size
small than 1.0 µm (Figure 14A1). Isotype antibody was used as negative
control (Figure 14A2).
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Transmission electron microscopy (TEM) showed that EMV had a spheroid
morphology with size ≥ 100 nm (Figure 14B), and they were heterogenous in
size. Nanoparticle

tracking analysis (NTA) was used to analyze the size and

concentration of EMVs. The NTA gave a vesicle size distribution from 40 to
653 nm with two peaks around 152 and 214 nm. ~ 80% of vesicles were larger
than 100nm and the vesicle count was 3.54 x 1010 per ml (Figure14 C1). The
screenshot of the same vesicles analyzed on the NanoSight LM10 showing a
heterogenous size population of vesicles (Figure14 C2).
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Count

Count

SSC-H

A: EMVs examined by FC

FSC-H

A2

A3

PE-H

Isotype - PE

PE-H

CD144 - PE

B:EMVs examined by TEM C: EMVs examined by NTA
B

C1

C2

3.54 x 1010 Particles/ml
Figure 14. Characterization of EMVs. Representative flow cytometric analysis
of endothelial EMVs (A). A1: the position of 1- (blue circle) and 2-µm (yellow
square) calibration beads and the R1 gate for MVs. A2: PE-conjugated isotype
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control. A3: PE-conjugated CD144. EMVs were defined as CD144 + events in
the gate of MVs. B: Isolated EMVs were observed by TEM; scale bar: 100 nm.
C: Measurement of EMV by NTA (C). C1 and C2: Size curve (white line) and
screen shot of video from NanoSight LM10 showing optimal light scatter from
EMVs that were retrieved from the up-membrane of 100 nm filter.

9. EMVs uptaken by target cells after co-incubation
Previous report indicated the possibility that protein and/or nucleic acids
(mRNAs, miRNA) are packaged into MVs and exosomes and can be taken up
by cells, acting as biomolecules. To elucidate whether EMVs can be uptaken
by target cell, we incubated HbmECs with PKH26-labeled EMVs and analyzed
after different time points. Immunofluorescence staining revealed that EMVs
were detectable in the cytoplasm of target cells after 0.5 hour treatment, and
that uptake in target cell was time dependent. To confirm that EMVs were
incorporated into the cytoplasm of cells, DAPI nuclear staining was also
applied. Fluorescence images showed that EMVs were internalized by
HbmECs (Figure 15A).

A: Microscope (HbmECs with PKH26-labeled EMVs)
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Figure 15. EMVs are incorporated by HbmECs in a time-dependent manner.
EMVs are incorporated by HbmECs in a time-dependent manner.
Representative figures for HbmECs incubated with PKH26-labeled EMVs for
24 hours (A). A1: DAPI staining (Blue). A2: PKH26-labeled EMVs (red). A3:
Merged image for DAPI/PKH26-labeled EMVs; scale bar: 200 µm. B:
Summarized data. Data are the mean ± SEM, n = 3.

10. EMVs improve tube formation ability of HbmECs compromised by
Ang II
The ability of HbmEC tube formation was attenuated in Ang II-treated group by
about 36% when compared with control (P<0.01; Figure 16B). Pretreatment
with EMVs enhanced tube formation ability of HbmECs by 43% (P<0.01;
Figure 16B) when compared with treatment with Ang II alone.
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Figure 16. EMVs improve tube formation ability of HbmEC compromised by
Ang II. A: Representative tube formation pictures. A1: Vehicle; A2: 10-7 M Ang
II; A3: 10-7 M Ang II + 10µg/ml EMVs; scale bar: 200 µm. B: Summarized data.
Data are the mean ± SEM, n = 4. ##P < 0.01 vs control; ++P<0.01 vs 10-7 M
Ang II.

11. EMVs reduce ROS production of HbmECs induced by Ang II
DHE fluorescent dye and flow cytometric analysis were used to investigate the
effect of Ang 1-7 on Ang II-induced ROS production. Results showed that DHE
fluorescence (red) was increased by about 2.7-fold after 24 hours stimulation
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of Ang II (Figure 17). Pretreatment with Ang 1-7 reduced the intensity of DHE
fluorescence by about 37% (P<0.01) when compared with Ang II, reflecting a
reduction in ROS generation. The effects that induced by Ang II and Ang 1-7
were neutralized by their receptor antagonist losartan and A779, respectively.
The protective effect of Ang 1-7 also was partially blocked by the PI3K inhibitor
(LY294002). Flow cytometric analysis showed that the peak of the signal
moved to the right, corresponding to increased DHE fluorescence, after
incubation with Ang II. This increase in fluorescence intensity was markedly
reduced, as evidenced by a leftward shift after treatment with Ang 1-7 in
addition to Ang II, which reflected a reduction in ROS generation.
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Figure 17. EMVs decrease Ang II-induced ROS production. A: Representative
DHE staining figures. A1: vehicle; A2: Ang II; A3: Ang II + EMVs; scale bar: 400
µm. B: Representative flow cytometric figures. B1: analysis control; B2: vehicle;
B3: Ang II; B4: Ang II + EMVs. C: Summarized data. Data are the mean ± SEM,
n = 4. ## P<0.01 vs Control, ++P<0.01 vs Ang II.
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12. EMVs increase the production of NO compromised by Ang II in
HbmECs
The NO production was lower (vs control; P<0.01; Figure 18) in the Ang
II-treated HbmECs. Pre-treatment of EMVs and endothelial exosomes induced
1.9- and 1.79-fold of NO production in Ang II-treated group, respectively.
(P<0.01).
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Figure 18. EMVs increase NO production of HbmECs compromised by Ang II.
A: Representative DAM-FM staining figures. A1: vehicle; A2: Ang II; A3:Ang II
+ EMVs; scale bar: 400 µm. B: Summarized data. Data are the mean ± SEM, n
= 4. ## P<0.01 vs Control, ++P<0.01 vs Ang II.
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13. EMVs up-regulate the expression of p-Akt/Akt and p-eNOS/eNOS
inhibited by Ang II in HbmECs
As we found that EMV could inhibit endothelial dysfunction and apoptosis
induced by Ang II, we hypothesized that EMVs might protect HbmEC
dysfunction and apoptosis by activating the Akt/eNOS activity. The western
blot analysis on p-Akt/Akt and p-eNOS/eNOS expression showed that Ang
II-induced down-regulation of Akt and eNOS were activated after EMV
treatment (Figure 19A). Treatment with Ang II decreased the expression of
p-Akt and p-eNOS (P<0.05). Whereas, pre-treatment with EMVs increased the
expression of p-Akt and p-eNOS expression in HbmECs, in the absence of
changes in Akt and eNOS protein levels (P<0.05; Figure 19A). This data
suggest that the protective effects of EMVs may be through activating
Akt/eNOS signaling pathway.
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Figure 19. EMVs up-regulate the expression of p-Akt/Akt and p-eNOS/eNOS
inhibited by Ang II in HbmECs A: Representative western blot bands showing
p-Akt/Akt and p-eNOS/eNOS expression in HbmECs. B Summarized data for
p-Akt/Akt and p-eNOS/eNOS expression. Values are the mean ± SEM, n = 4.
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P< 0.05 vs control; ++P<0.05 vs Ang II.
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VI.

DISCUSSION

The major findings of this study are as follows: 1) Ang 1-7 counteracts the
deleterious effects of Ang II-induced endothelial dysfunction and apoptosis
through direct inhibition of Nox2 activity and activation of the PI3K/Akt/eNOS
signaling pathway. 2) EMVs can also protect endothelial cells against Ang
II-induced dysfunction and apoptosis by decreasing ROS production and
activating the Akt/eNOS/NO pathway.

Endothelial dysfunction is a condition in which the endothelium of blood
vessels does not function normally. It is characterized by reduced vasodilation,
proinflammatory state and prothrombic properties. Endothelial dysfunction is
an important early event in the pathogenesis of atherosclerosis, contributing to
plaque initiation and progression. The severity of endothelial dysfunction has
been shown to have prognostic value for cardiovascular events. Correction of
endothelial dysfunction may be associated with reduced cardiovascular risk.
Mechanisms that participate in the reduced vasodilatory responses in
endothelial dysfunction include reduced NO, increased oxidative stress.
Apoptosis (early programmed cell death) of ECs is associated phenomenon. It
has been documented that upregulation of vasoactive peptides such as Ang II
induces endothelial dysfunction in vivo and in vitro. In addition, studies
indicated that ACE inhibitors and AT-1 receptor blockers have protective
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effects on ECs. Ang 1-7 is a vasodilator peptide counteracting many
deleterious effects of Ang II induced. However, the detailed mechanism is not
clear.

In this study, we demonstrated that the ability of HbmEC tube formation is
impaired by Ang II. We also found that Ang II decreases the expression levels
of p-Akt and p-eNOS, and NO production in HbmECs; however, increases
Nox2 expression and ROS production in the HbmECs. These findings are
supported by previous evidence demonstrating that the RAS plays a key role
in modulating EC function through regulating NO and ROS production [16;22].
Recently, it has been suggested that Ang II inhibits Akt-induced eNOS
activation and subsequent NO release in ECs [69] and that Ang II infusion
decreases NO production in aorta by causing eNOS uncoupling.
One of the major and interesting findings of the present study is that
pretreatment with Ang 1-7 enhances HbmEC tube formation ability decreased
by Ang II. Those effects of Ang 1-7 can be partially abolished by Mas receptor
antagonist (A779), suggesting that Ang 1-7 counteract the effect of Ang II via
Mas receptor dependent pathway.

Previous studies have suggested that Ang1–7 could against Ang II-induced
apoptosis in other types of ECs. Consistent with previous reports, we found
that Ang II enhances apoptosis and that Ang 1-7 inhibits Ang II-induced
apoptosis in HbmECs. Alone, Ang1–7 had no effect on HbmEC apoptosis. The
AT-1 receptor antagonist losartan almost completely abolished the Ang II
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induced apoptosis. The Mas receptor antagonist A-779 almost completely
abolished the suppression by Ang1–7 of Ang II-induced apoptosis, suggesting
that Ang1–7 speciﬁcally ameliorates Ang II-induced apoptosis. The data
suggest that Ang 1–7 may be used to improve Ang II-induced apoptosis and
consequently improve Ang II-associated diseases. Interestingly, preincubation
of PI3K inhibitor LY294002 partially abolished the suppression by Ang 1-7 on
Ang II-induced apoptosis, suggesting the PI3K activation is also involved in the
antiapoptotic effects of Ang 1-7 induced. In contrast with its anti-apoptotic
effects, Ang1–7 has also been reported to induce apoptosis in circulating
ﬁbrocytes and human lung cancer cells . Thus, the anti-apoptotic effect of Ang
1–7 is dependent on the cell type. We are not certain that the anti-apoptotic
effects of Ang 1-7 will be applicable to all types of ECs.

Oxidative stress is one of the important factors that increase endothelial
permeability. ROS play an important role in EC dysfunction and a family of
NADPH oxidases (Noxs) is the major source of ROS involved in redox
signaling. Previous studies have also proven that Ang II increase ROS
production through activates Nox pathway in various cell types, including
vascular smooth muscle, fibroblasts, ECs and cardiomyocytes. However,
vascular Noxs are expressed in a cell-specific manner, with ECs expressing
mainly Nox2 and Nox4; vascular smooth muscle cells, Nox1, Nox2, and Nox4;
and fibroblasts, Nox2 and Nox4. Our study demonstrated that Ang II was able
to induce overproduction of ROS and activation of Nox2 activity in cultured
HbmECs. Whereas, preincubation of Ang 1-7 can block Ang II-induced ROS
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production, through down-regulation of Nox2 activity. The effects of Ang II and
Ang 1-7 induced were abolished by their selective receptor antagonist losartan
and A779, respectively. Thus, Ang 1-7 attenuates Ang II-induced oxidative
stress through Mas receptor.

Ang II induced overproduction of ROS seem also to be involved in the
mediation of endothelial injury leading to programmed cell death or apoptosis.
Recently, it has been suggested that Ang II inhibits Akt-induced eNOS
activation and NO release in ECs. Of note, in addition to activation of NADPH
oxidase and inhibition of Akt/eNOS signaling cascades, other cellular signaling
also involved in Ang II-induced deleterious effects, such as protein kinase C
activation, calcium (Ca2+) loading and phosphorylation of mitogen-activated
protein kinase (MAPK). In this study, we evaluated the possible mechanisms
by which Ang 1-7 may positively interfere in the RAS signaling in HbmECs.
Our data demonstrates that the exposure of HbmECs to Ang 1-7 was directly
able to activate the signaling pathway producing NO, a molecule that
possesses some vasoprotective effects. Akt and eNOS are two crucial
enzymes in this signaling pathway. Their activation is related to a serine
phosphorylation, which is significantly inhibited by Ang II through the AT1R
stimulation. On the contrary, Ang 1-7 counteracts the inhibitory effects of Ang II
on them. The use of receptor antagonists indicates that the effects of Ang 1–7
are largely mediated by Mas receptor. Moreover, the PI3K activation is an
important step for the Akt recruitment that it is necessary to activate the eNOS
signaling and subsequently NO production. Our study confirms that the
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PI3K/Akt axis is also crucial in the effects mediated by Ang1–7. In fact, Ang1–7
is able to promote the Akt and eNOS serine phosphorylation that is inhibited by
the LY294002, a selective PI3K inhibitor. Our data suggest that the exposure
of HbmECs to Ang1–7 is directly able to activate the signaling pathway
producing NO, a key biological molecule involved in the preservation of
endothelial function and vascular integrity. The biological relevance of this
finding is supported by the demonstration that Ang1–7 is able to induce an
endothelium-dependent vasodilation in mice arteries, similarly to that exerted
by muscarinic receptor stimulation. This data add new information to previous
reports showing the protective role of Ang 1-7 in cells. Our results highlight the
importance of the Ang 1-7/Mas axis as a potential regulator of endothelial
function.

The most exciting finding of this study is that we demonstrate that EMVs can
be uptaken by target HbmECs and the incorporation of EMV inhibits Ang
II-induced dysfunction and apoptosis in HbmECs. Activation of Akt/eNOS
activity is possibly involved in EMV-mediated protection against apoptosis. We
use flow cytometric analysis to assess the surface markers of EMVs, we found
EMVs were carry their parent proteins and express the markers as their parent
cells (CD144 for endothelial cells). We examined the size and morphology of
EMV using the TEM, we found the EMVs are membrane-bound vesicles and
had a spheroid morphology. The size is around 100 nm or bigger, that's
consistent with other's reports. The NTA reveal that EMVs have a
heterogenous size population. Since this is only one time experiment, we did
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not adopt this EMV concentration for our later experiments but use the protein
concentration of 10µg/ml to our further experiments. In this study, we also
demonstrate that EMVs can be uptaken by target cell in a time-dependent
manner and we apply for the time point 24 hours as our further experiment
according to others reports.

EMVs have been shown to act as a paracrine mediator as they can merge with
target cells for exerting their functions. Several studies have demonstrated that
EPC-MVs can protect ECs from cell dysfunction and apoptosis by Ang II and
other risk factors. But not much data is available for the role of EMVs in
regulating endothelial function. In this study, we generated MVs from HbmECs
which starvation and examined its effects of on HbmEC treated with Ang II. We
found the tube formation ability and NO production that were compromised by
Ang II were increased after EMV treatment, accompany with decreased ROS
production. More interestingly, the expression of Akt and eNOS were
up-regulated in HbmECs treated with EMVs when compared to Ang II
treatment. This data indicates that EMVs could protect HbmEC dysfunction
through activating NO pathway and decreasing ROS production.
We demonstrated that inhibition of Akt/eNOS signaling pathway was involved
in endothelial dysfunction induced by Ang II. EMVs activated the Ang IIinduced Akt/eNOS inhibition after Ang II treatment. These findings, in
accordance with other data, MVs regulate Akt/eNOS activity and thereby
mediate protective effects. Nevertheless, the detailed mechanisms of their
roles need further investigation.
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VII.

CONCLUSION

Our data demonstrate that Ang 1-7 could protect cerebral endothelial cell
dysfunction and apoptosis induced by Ang II, this functional role might rely on
Nox/ROS and PI3K/Akt/eNOS pathway. Also, our data suggests that EMVs
could protect Ang II-induced cerebral endothelial dysfunction, their functional
role might rely on in the control of ROS production and Akt/eNOS/NO pathway
in the target cells. This finding indicates that both Ang 1-7 and EMVs could be
used to treat Ang II-induced endothelial dysfunction.
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